GLORY-2: 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Chinese adults with obesity, with or without type 2 diabetes
n=462
Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.
Chinese population; 9 mg regimen differs from 4/6 mg GLORY-1; detailed subgroup extraction ongoing.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Phase 3 high-dose study demonstrated clinically meaningful weight reduction; full outcome-by-outcome extraction retained in source review queue.